# Trade Mark Journal No.2026/001 2 January 2026

## WO0000001892393 (5)

Office of origin: United States of America

Date of International Registration:21 November 2025
Date of designation in the UK: 21 November 2025

Class 5
  Pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy; pharmaceutical preparations for frataxin replacement therapy.

Larimar Therapeutics, Inc.

Representative: Keith Toms, Esq. McCarter & English, LLP, 265 Franklin Street, Boston MA 02110, UNITED STATES OF AMERICA